Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis

Cancer Biology and Therapy

Volumn 8, Issue 17, 2009, Pages 1615-1622

  Parada, Belmiro ^a,b   Sereno, José ^a   Reis, Flávio ^a,c   Teixeira Lemos, Edite ^a   Garrido, Patricia ^a   Pinto, Angela Filipa ^a   Cunha, Maria Fernanda ^b   Pinto, Rui ^d   Mota, Alfredo ^b   Figueiredo, Arnaldo ^a,b   Teixeira, Frederico ^a,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d Pharmacology and Pharmacotoxicology Unit   (Portugal)

Author keywords

Bladder cancer; Chemoprevention; Cyclooxygenase 2 inhibition; Inflammation; Oxidative stress; Proliferation; Rat model

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CELECOXIB; CREATININE; CYCLOOXYGENASE 2; HEMOGLOBIN; INTERLEUKIN 1BETA; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UREA; URIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER PAPILLOMA; CANCER MODEL; CARCINOMA IN SITU; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DYSPLASIA; ENZYME INHIBITION; ERYTHROCYTE COUNT; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HYPERPLASIA; INCIDENCE; INFLAMMATION; KIDNEY; KIDNEY FUNCTION; LEUKOCYTE COUNT; LIPID PEROXIDATION; LIVER; LIVER WEIGHT; MALE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; RETICULOCYTE; THROMBOCYTE COUNT; TUMOR GROWTH; TUMOR VOLUME; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; UROTHELIUM;

ANIMALS; ANTICARCINOGENIC AGENTS; CELL GROWTH PROCESSES; CYCLOOXYGENASE 2 INHIBITORS; INFLAMMATION; MALE; OXIDATIVE STRESS; PYRAZOLES; RATS; RATS, WISTAR; SULFONAMIDES; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 70350306703     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.17.9199     Document Type: Article

References (46)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18:581-592
2. Grasso M. Bladder cancer: A major public health issue. Eur Urol Suppl 2008; 7:510-515
3. Pisani P, Bray F, Parkin DM. Estimates of world-wide prevalence of cancer for 25 sites in the adult prevalence. Int J Cancer 2002; 97:72-81. (Pubitemid 33104397)
4. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2,596 patients from seven EORTC trials. Eur Urol 2006; 49:466-477 (Pubitemid 43259554)
5. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging, grading and diagnosis. Urology 2005; 66:4-34. (Pubitemid 43049607)
6. Sangar VK, Ragavan N, Matanheleia SS, Watson MW, Blades RA. The economic consequences of prostate and bladder cancer in UK. BJU Int 2005; 95:59-63. (Pubitemid 350020870)
7. Malkowicz SB, van Poppel H, Mickisch G, Pansadoro V, Thüroff J, Soloway MS, et al. Muscle-invasive urothelial carcinoma of the bladder. Urology 2007; 69:3-16.
8. Evans C, Debruyne F, Payne H, Solsona E, Teillac P, Tubaro A. Bladder cancer: management and future directions. Eur Urol Suppl 2007; 6:365-373 (Pubitemid 46149478)
9. Zeegers MP, Tan FE, Dorant E, Van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 2000; 66:4-34.
10. Kogevinas M, 't Mannetje A, Cordier S, Ranft U, González CA, Vineis P, et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control 2003; 14:907-914
11. Wolff DJ. The genetics of bladder cancer: a cytogeneticist's perspective. Cytogenet Genome Res 2007; 118:177-181 (Pubitemid 350125254)
12. Fukushima S, Hirose M, Tsuda H, Shirai T, Hirao K. Histological classification of urinary bladder cancers in rats induced by N-butyl-n-(4-hydroxybutyl)nitrosamine. Gann 1976; 67:81-90.
13. Montironi R, Mazzucchelli R. Preneoplastic lesions and conditions of the urinary bladder. EAU Update Series 2003; 1:53-63. (Pubitemid 40411073)
14. Sauter G, Algaba F, Amin M, Busch C, Cheville J, Gasser T, et al. Tumours of the urinary system: non-invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein Jl, Sesterhenn I, (eds.,) WHO classification of classification of tumours of the urinary system and male genital organs. Lyon: IARCC Press 2004; 29-34.
15. Gofrit ON, Birman T, Ayesh S, Ohana P, Hochberg A. Chemically induced bladder cancer-A sonographic and norphologic description. Urology 2006; 68:231-235 (Pubitemid 44037755)
16. Leppert JT, Shvarts O, Kawaoka K, Lieberman R, Belldegrun AS, Pantuck AJ. Prevention of bladder cancer: A review. Eur Urol 2006; 49:226-234
17. Hameed DA, el-Metwally TH. The effectiveness of retinoic acid treatment in bladder cancer: impact on recurrence, survival and TGFalpha and VEGF as end-point biomarkers. Cancer Biol Ther 2008; 7:92-100.
18. Ristimäki A, Nieminen O, Saukkonen K, Hotakainen K, Nordiling S, Haglund C. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 2001; 158:849-853 (Pubitemid 32221778)
19. Kam PC, See AU. Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia 2000; 55:442-449 (Pubitemid 30301443)
20. Harris RE. Cyclooxygenase-2 (COX-2) and the inflammogenesis of cancer. Subcell Biochem 2007; 42:93-126.
21. de Heer P, Sandel MH, Guertens G, de Boeck G, Koudijs MM, Nagelkerke JF, et al. Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. Cancer Chemother Pharmacol 2008; 62:811-819
22. Keller JJ, Giardiello FM. Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol Ther 2003; 2:140-149
23. Narayanan NK, Nargi D, Horton L, Reddy BS, Bosland MC, Narayanan BA. Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib. Prostate 2009; 69:133-141
24. Hattori K, Iida K, Joraku A, Tsukamoto S, Akaza H, Oyasu R. Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int 2006; 97:640-643
25. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007; 121:2381-2386 (Pubitemid 350022406)
26. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, et al. Celecoxib inhibits N-Butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in Male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000; 60:5599-5602
27. DeGortari AE, Han C, Glickman LT. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000; 46:221-226 (Pubitemid 30728656)
28. Okajima E, Denda A, Ozono S, Takahama M, Akai H, Sasaki Y, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl) nitrosamine. Cancer Res 1998; 58:3028-3031 (Pubitemid 28335083)
29. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275:11397-11403 (Pubitemid 30212792)
30. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000; 164:820-825 (Pubitemid 30637640)
31. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002; 94:585-591 (Pubitemid 34498645)
32. Leivonen SK, Kähäri VM. Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer 2007; 121:2119-2124 (Pubitemid 47585589)
33. Van Horssen R, Ten Hagen TL, Eggermont AM. TNFalpha in cancer treatment: molecular insights, antitumour effects and clinical utility. Oncologist 2006; 11:397-408.
34. Gee J, Lee IL, Jendiroba D, Fischer SM, Grossman HB, Sabichi AL. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 2006; 15:471-477
35. Mohammed SI, Dhawan D, Abraham S, Snyder PW, Waters DJ, Craig BA, et al. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol Cancer Ther 2006; 5:329-336
36. Suleyman H, Demircan B, Karagöz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007; 59:247-258 (Pubitemid 47299726)
37. Mansure JJ, Nassim R, Kassouf W. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol Ther 2009; 8:6-15.
38. Dhawan D, Jeffreys AB, Zheng R, Stewart JC, Knapp DW. Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol Cancer Ther 2008; 7:897-904. (Pubitemid 351551043)
39. Yalçin O, Karatas F, Erulas FA, Ozdemir E. The levels of glutathione peroxidase, vitamin A, E, C and lipid peroxidation in patients with transitional cell carcinoma of the bladder. BJU Int 2004; 93:863-866
40. Gupta S, Sarotra P, Aggarwal R, Dutta N, Agnihotri N. Role of oxidative stress in celecoxib-induced renal damage in wistar rats. Dig Dis Sci 2007; 52:3092-3098 (Pubitemid 47512556)
41. Alhan E, Kalyoncu NI, Ercin C, Kural BV. Effects of the Celecoxib on the acute necrotizing pancreatitis in rats. Inflammation 2004; 28:303-309 (Pubitemid 41204383)
42. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, Celecoxibe, administered during different stages of carcinogenesis. Cancer Res 2000; 60:293-297 (Pubitemid 30070754)
43. Young I, Cha, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Ann Rev Med 2007; 58:239-252
44. Mohammed SI, Knapp DW, Bostwick DG, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999;59:5647-5650
45. Estepa V, Ródenas S, Martin MC. Optimización de un método para la determinación lipidica em suero humano. Anal Real Acad Farm 2001; 67:1-17.
46. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "anti-oxidant power": the FRAP assay. Anal Biochem 1996; 239:70-76